Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation study.
To analyze the spectrum of diseases in patients with chronic hepatitis B virus (HBV) infection and their association with patient clinicopathologic characteristics and the effect of antiviral therapy on the spectrum of diseases in the study cohort. We retrospectively reviewed the clinicopathologic and virologic records of patients with chronic HBV infection hospitalized at our institution during 2011. Demographic data, hepatitis B e antigen (HBeAg) status and HBV DNA (log10 IU/ml) were obtained. A total of 1,619 patients were included; 272 (17.2 %) patients received antiviral therapy for a mean duration of 24.5 ± 18.3 months, and 71.0 % (198/279) patients were compliant with their antiviral therapy. HBeAg-positive patients had a markedly higher rate of moderate and severe CHB than HBeAg-negative patients (p < 0.001) but a significantly lower rate of liver cirrhosis (p < 0.001). The rate of severe and fulminant CHB was significantly lower in patients receiving antiviral therapy than in those not receiving antiviral therapy. Patients receiving antiviral therapy exhibit a different spectrum of diseases from patients not receiving such therapy.